Abstract： Objective:To investigate the mechanism of modified Zhujing Pills(驻景丸)in treating age-related macular degeneration(AMD)with Ganshenbuzu(肝肾不足)based on plasma proteomics.Methods:Using TMT proteomics technology,differential proteins in plasma before and after treatment with modified Zhujing Pills in normal individuals and AMD patients with Ganshenbuzu were screened.Differential proteins were subjected to clustering analysis,protein-protein interaction(PPI)analysis,GO,pathway functional annotation,and enrichment analysis.Five proteins with the highest degree of PPI analysis were selected as candidate target proteins.ELISA was used to detect the levels of plasma target proteins in AMD patients for in vivo validation.Pathway enrichment analysis was performed to identify the main signaling pathways.Western blot was used to detect the expression levels of pathway-related proteins in ARPE-19 cells after intervention with serum containing modified Zhujing Pills for in vitro validation.Results:Five main candidate target proteins were screened out,namely CDH1,CDC42,PTPRK,CYCS,and PTPRG.In vivo validation results showed that compared with the results before treatment,the plasma levels of target proteins CDH1,PTPRK,and CYCS increased after treatment(P＜0.01),while CDC42 and PTPRG decreased(P＜0.01).Pathway enrichment analy-sis revealed that the main signaling pathways were epithelial-mesenchymal transition(EMT)and Wnt signaling pathways.In vitro validation results showed that modified Zhujing Pills could inhibit EMT and Wnt signaling pathways.Conclusion:The mechanism of modified Zhujing Pills in treating AMD with Ganshenbuzu may involve the regulation of EMT and Wnt signaling pathways.